uniQure Begins Phase I/IIa Trial for AMT-260 Therapy

uniQure ( (QURE) ) has shared an update.

uniQure N.V. has commenced the dosing of the first patient in its Phase I/IIa clinical trial of AMT-260, a promising gene therapy for refractory mesial temporal lobe epilepsy, a condition affecting many with limited treatment options. AMT-260 aims to reduce seizures via a one-time administration, offering hope for those unresponsive to existing treatments. As the trial continues, uniQure anticipates further program updates soon.

See more insights into QURE stock on TipRanks’ Stock Analysis page.